249 related articles for article (PubMed ID: 37385752)
1. AR activates YAP/TAZ differentially in prostate cancer.
Salem O; Jia S; Qian BZ; Hansen CG
Life Sci Alliance; 2023 Sep; 6(9):. PubMed ID: 37385752
[TBL] [Abstract][Full Text] [Related]
2. The Hippo Pathway in Prostate Cancer.
Salem O; Hansen CG
Cells; 2019 Apr; 8(4):. PubMed ID: 31018586
[TBL] [Abstract][Full Text] [Related]
3. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
[TBL] [Abstract][Full Text] [Related]
4. Emerging roles for the YAP/TAZ transcriptional regulators in brain tumour pathology and targeting options.
Strepkos D; Markouli M; Papavassiliou KA; Papavassiliou AG; Piperi C
Neuropathol Appl Neurobiol; 2022 Feb; 48(2):e12762. PubMed ID: 34409639
[TBL] [Abstract][Full Text] [Related]
5. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
[TBL] [Abstract][Full Text] [Related]
6. YAP antagonizes TEAD-mediated AR signaling and prostate cancer growth.
Li X; Zhuo S; Cho YS; Liu Y; Yang Y; Zhu J; Jiang J
EMBO J; 2023 Feb; 42(4):e112184. PubMed ID: 36588499
[TBL] [Abstract][Full Text] [Related]
7. The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises.
Ortega Á; Vera I; Diaz MP; Navarro C; Rojas M; Torres W; Parra H; Salazar J; De Sanctis JB; Bermúdez V
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008857
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Hippo/YAP/TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers.
Howard A; Bojko J; Flynn B; Bowen S; Jungwirth U; Walko G
Exp Dermatol; 2022 Oct; 31(10):1477-1499. PubMed ID: 35913427
[TBL] [Abstract][Full Text] [Related]
9. Control of stem cell renewal and fate by YAP and TAZ.
Driskill JH; Pan D
Nat Rev Mol Cell Biol; 2023 Dec; 24(12):895-911. PubMed ID: 37626124
[TBL] [Abstract][Full Text] [Related]
10. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
Zhu J; Wu T; Lin Q
Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
[TBL] [Abstract][Full Text] [Related]
11. Induction of AP-1 by YAP/TAZ contributes to cell proliferation and organ growth.
Koo JH; Plouffe SW; Meng Z; Lee DH; Yang D; Lim DS; Wang CY; Guan KL
Genes Dev; 2020 Jan; 34(1-2):72-86. PubMed ID: 31831627
[TBL] [Abstract][Full Text] [Related]
12. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
[TBL] [Abstract][Full Text] [Related]
13. Quantitative Real-Time PCR to Measure YAP/TAZ Activity in Human Cells.
Cao X; Zhao B
Methods Mol Biol; 2019; 1893():137-152. PubMed ID: 30565132
[TBL] [Abstract][Full Text] [Related]
14. YAP and TAZ play a crucial role in human erythrocyte maturation and enucleation.
Damkham N; Lorthongpanich C; Klaihmon P; Lueangamornnara U; Kheolamai P; Trakarnsanga K; Issaragrisil S
Stem Cell Res Ther; 2022 Sep; 13(1):467. PubMed ID: 36076260
[TBL] [Abstract][Full Text] [Related]
15. A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.
Shreberk-Shaked M; Dassa B; Sinha S; Di Agostino S; Azuri I; Mukherjee S; Aylon Y; Blandino G; Ruppin E; Oren M
Cancer Res; 2020 Oct; 80(19):4145-4157. PubMed ID: 32816858
[TBL] [Abstract][Full Text] [Related]
16. Repression of SLC22A3 by the AR-V7/YAP1/TAZ axis in enzalutamide-resistant castration-resistant prostate cancer.
Seo E; Jee B; Chung JH; Song W; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Kang M
FEBS J; 2023 Mar; 290(6):1645-1662. PubMed ID: 36254631
[TBL] [Abstract][Full Text] [Related]
17. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers.
Luo M; Xu Y; Chen H; Wu Y; Pang A; Hu J; Dong X; Che J; Yang H
Eur J Med Chem; 2022 Dec; 244():114847. PubMed ID: 36265280
[TBL] [Abstract][Full Text] [Related]
18. YAP/TAZ Initiates Gastric Tumorigenesis via Upregulation of MYC.
Choi W; Kim J; Park J; Lee DH; Hwang D; Kim JH; Ashktorab H; Smoot D; Kim SY; Choi C; Koh GY; Lim DS
Cancer Res; 2018 Jun; 78(12):3306-3320. PubMed ID: 29669762
[TBL] [Abstract][Full Text] [Related]
19. HERC3 promotes YAP/TAZ stability and tumorigenesis independently of its ubiquitin ligase activity.
Yuan B; Liu J; Shi A; Cao J; Yu Y; Zhu Y; Zhang C; Qiu Y; Luo H; Shi J; Cao X; Xu P; Shen L; Liang T; Zhao B; Feng XH
EMBO J; 2023 Feb; 42(4):e111549. PubMed ID: 36598329
[TBL] [Abstract][Full Text] [Related]
20. Insights into recent findings and clinical application of YAP and TAZ in cancer.
Franklin JM; Wu Z; Guan KL
Nat Rev Cancer; 2023 Aug; 23(8):512-525. PubMed ID: 37308716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
